Alpha 2.0
Login Register
» Authors » Gary S Rubin

Gary S Rubin

Explore the profile of Gary S Rubin including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 102
Citations 3587
Followers 0
Related Specialties
Ophthalmology
Biomedical Engineering
General Medicine
Top 10 Co-Authors
Michael D Crossland
Adnan Tufail
Fred K Chen
Lyndon da Cruz
Praveen J Patel
Pradeep Y Ramulu
Catey Bunce
Frank G Holz
Hannah M P Dunbar
Marko Nardini
Published In
Invest Ophthalmol Vis Sci
Ophthalmology
Optom Vis Sci
Ophthalmic Physiol Opt
Vision Res
Affiliations
Soon will be listed here.
Recent Articles
1.
Eccentric Viewing Training for Age-Related Macular Disease: Results of a Randomized Controlled Trial (the EFFECT Study)
Rubin G, Crossland M, Dunbar H, Brown G, Petriti B, Roche H, et al.
Ophthalmol Sci . 2024 Jan; 4(2):100422. PMID: 38187128
Purpose: Eccentric viewing training for macular disease has been performed for > 40 years, but no large studies including control groups have assessed the benefits of this training. The EFFECT...
2.
Test-Retest Variability and Discriminatory Power of Measurements From Microperimetry and Dark Adaptation Assessment in People With Intermediate Age-Related Macular Degeneration - A MACUSTAR Study Report
Higgins B, Montesano G, Dunbar H, Binns A, Taylor D, Behning C, et al.
Transl Vis Sci Technol . 2023 Jul; 12(7):19. PMID: 37477933
Purpose: The purpose of this study was to assess test-retest variability and discriminatory power of measures from macular integrity assessment (S-MAIA) and AdaptDx. Methods: This is a cross-sectional study of...
3.
Repeatability and Discriminatory Power of Chart-Based Visual Function Tests in Individuals With Age-Related Macular Degeneration: A MACUSTAR Study Report
Dunbar H, Behning C, Abdirahman A, Higgins B, Binns A, Terheyden J, et al.
JAMA Ophthalmol . 2022 Jun; 140(8):780-789. PMID: 35737401
Importance: There is a need for validated clinical end points that are reliably able to quantify potential therapeutic effects of future treatments targeting age-related macular degeneration (AMD) before the onset...
4.
Validation of a Vision-Guided Mobility Assessment for -Associated Retinal Dystrophy
Kumaran N, Ali R, Tyler N, Bainbridge J, Michaelides M, Rubin G
Transl Vis Sci Technol . 2020 Sep; 9(10):5. PMID: 32953245
Purpose: To validate a vision-guided mobility assessment for individuals affected by -associated retinal dystrophy (-RD). Methods: In this comparative cross-sectional study, 29 subjects, comprising 19 subjects with -RD and 10...
5.
Harmonization of Outcomes and Vision Endpoints in Vision Restoration Trials: Recommendations from the International HOVER Taskforce
Ayton L, Rizzo 3rd J, Bailey I, Colenbrander A, Dagnelie G, Geruschat D, et al.
Transl Vis Sci Technol . 2020 Sep; 9(8):25. PMID: 32864194
Translational research in vision prosthetics, gene therapy, optogenetics, stem cell and other forms of transplantation, and sensory substitution is creating new therapeutic options for patients with neural forms of blindness....
6.
Clinical study protocol for a low-interventional study in intermediate age-related macular degeneration developing novel clinical endpoints for interventional clinical trials with a regulatory and patient access intention-MACUSTAR
Terheyden J, Holz F, Schmitz-Valckenberg S, Luning A, Schmid M, Rubin G, et al.
Trials . 2020 Jul; 21(1):659. PMID: 32682441
Background: There is an unmet need for treatment options in intermediate age-related macular degeneration (iAMD). However, for any new interventions to be tested in clinical trials, novel currently unavailable clinical...
7.
Individualizing Therapy for Neovascular Age-Related Macular Degeneration with Aflibercept (VITAL): A Two-Year Prospective, Interventional Single-Centre Trial
Patel P, Jayaram H, Eleftheriadou M, Vazquez-Alfageme C, Islam N, Rubin G, et al.
Ophthalmol Ther . 2020 Jun; 9(3):563-576. PMID: 32557168
Aims: To report the mean change in Early Treatment Diabetic Retinopathy Study (ETDRS) best-corrected visual acuity (BCVA) and reading performance (reading acuity and maximum reading speed (MRS) using the MNREAD...
8.
Femtosecond Laser-Assisted Cataract Surgery Versus Phacoemulsification Cataract Surgery (FACT): A Randomized Noninferiority Trial
Day A, Burr J, Bennett K, Bunce C, Dore C, Rubin G, et al.
Ophthalmology . 2020 May; 127(8):1012-1019. PMID: 32386810
Purpose: To report the 3-month results of a randomized trial (Femtosecond Laser-Assisted Cataract Trial [FACT]) comparing femtosecond laser-assisted cataract surgery (FLACS) with standard phacoemulsification cataract surgery (PCS). Design: Multicenter, randomized...
9.
Microperimetry and swept-source optical coherence tomography in the assessment of the preferred retinal locus in a child with macular retinoblastoma in the remaining eye
Johnson K, McLean A, Rubin G, Papastefanou V, Hussain A, Cai Y, et al.
J AAPOS . 2018 Dec; 23(2):115-117. PMID: 30502422
Assessing the visual capabilities that remain to children affected with bilateral retinoblastoma has relied on psychophysical tests based on recognition visual acuity. We report a case in which fundus-driven perimetry...
10.
MACUSTAR: Development and Clinical Validation of Functional, Structural, and Patient-Reported Endpoints in Intermediate Age-Related Macular Degeneration
Finger R, Schmitz-Valckenberg S, Schmid M, Rubin G, Dunbar H, Tufail A, et al.
Ophthalmologica . 2018 Aug; 241(2):61-72. PMID: 30153664
Purpose: Currently, no outcome measures are clinically validated and accepted as clinical endpoints by regulatory agencies for drug development in intermediate age-related macular degeneration (iAMD). The MACUSTAR Consortium, a public-private...